Orlistat , >97.0%(HPLC) , 96829-58-2
Synonym(s):
(−)-Tetrahydrolipstatin;N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester;Orlistat;Ro-18-0647
CAS NO.:96829-58-2
Empirical Formula: C29H53NO5
Molecular Weight: 495.73
MDL number: MFCD05662360
EINECS: 639-755-1
| Pack Size | Price | Stock | Quantity |
| 100MG | RMB31.20 | In Stock |
|
| 250MG | RMB39.20 | In Stock |
|
| 1G | RMB56.80 | In Stock |
|
| 5G | RMB100.00 | In Stock |
|
| 25G | RMB476.00 | In Stock |
|
| 100G | RMB1268.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | <50 °C |
| Boiling point: | 615.9±30.0 °C(Predicted) |
| alpha | D20 -32.0° (c = 1 in chloroform) |
| Density | 0.976±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO: 19 mg/mL |
| form | solid |
| pka | 14.59±0.23(Predicted) |
| color | white |
| biological source | synthetic (organic) |
| Merck | 14,6869 |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 week. |
| InChIKey | AHLBNYSZXLDEJQ-FWEHEUNISA-N |
| SMILES | C(O[C@H](C[C@H]1[C@H](CCCCCC)C(=O)O1)CCCCCCCCCCC)(=O)[C@H](CC(C)C)NC=O |
| CAS DataBase Reference | 96829-58-2(CAS DataBase Reference) |
Description and Uses
Orlistat was launched in the UK as Xenical for the long-term treatment of obesity, preferably in conjunction with a moderately reduced calorie diet. Orlistat is a tetrahydro-derivative of the natural hypolipaemic lipstatin (from Streptomyces toxyfncini) and can be obtained either by hydrogenation of lipstatine or by several different synthetic ways involving many steps from ( S ) - rnalic acid. Orlistat is a potent inhibitor of gastrointestinal lipases required for the lipolysis and digestion of dietary fat, in particular of pancreatic lipase ; as a result, it prevents the absorption of about one third of the fat contained in food and acts as an effective weight-reducing therapy. The outcomes of several clinical trials involving thousands of obese patients showed that Orlistat promotes a significant weight loss (often between 5 and 10% after one year) and improves cardiovascular risk factors such as total cholesterol, LDL/HDL ratio, blood glucose levels, insulin, blood pressure. Orlistat has minimal systemic absorption, the majority of the compound itself being recovered in the feces ; it does not affect other gastrointestinal processes, or the absorption of other rnacronutrients such as carbohydrates and proteins.
Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor.
Safety
| Symbol(GHS) | ![]() GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H412 |
| Precautionary statements | P273 |
| PPE | Eyeshields, Gloves, type N95 (US) |
| WGK Germany | 3 |
| RTECS | OH3167600 |
| HS Code | 29322090 |
| Storage Class | 11 - Combustible Solids |
| Hazardous Substances Data | 96829-58-2(Hazardous Substances Data) |




